- IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
-
The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.
- -
-
Paragraph 00379
(2017/11/04)
-
- Oral drug composition for vascular endothelial growth factor inhibitor
-
The invention belongs to the medical field, particularly relates to an oral drug composition for inhibiting salt of a compound of formula I (shown in the description) of a VEGF, pharmaceutical use of the oral drug composition and a pharmaceutical preparation and particularly aims at treatment of tumors and angiogenesis. The invention further relates to a synthetic method of the compound.
- -
-
Paragraph 0110; 0146; 0169; 0170-0173; 0205-0209
(2017/07/19)
-
- Injection pharmaceutical composition for vascular endothelial growth factor inhibitor
-
The invention belongs to the field of medicine, particularly relates to an injection pharmaceutical composition for inhibiting salt of a compound of formula I (shown in the description) of a VEGF, pharmaceutical use of the injection pharmaceutical composition and a pharmaceutical preparation and particularly aims at treatment of tumors and angiogenesis. The invention further relates to a synthetic method of the compound.
- -
-
Paragraph 0178; 0179; 0180; 0181; 0182; 0214-0218
(2017/07/22)
-
- A method for inhibiting VEGF of the solid oral pharmaceutical composition (by machine translation)
-
The invention belongs to the field of medicine, in particular to inhibit VEGF of the formula I compound and salt solid pharmaceutical composition, the pharmaceutical use and pharmaceutical formulations, particularly with respect to the tumor, the treatment of angiogenesis. The invention also relates to the method for synthesizing the compounds. (by machine translation)
- -
-
Paragraph 0176; 0177; 0178; 0179; 0180; 0212-0216
(2017/07/20)
-
- Vascular endothelial growth factor inhibitor compound
-
The invention relates to a vascular endothelial growth factor inhibitor compound. The invention belongs to the medical field and particularly relates to salt of a compound of formula I (shown in the description). The invention further relates to synthetic method of the compound, pharmaceutical use of the compound and a pharmaceutical preparation and particularly aims at treatment of tumors and angiogenesis.
- -
-
Paragraph 0170; 0171; 0172; 0173; 0174; 0205-0210
(2017/07/21)
-
- VEGF (vascular endothelial growth factor)-inhibiting dry powder inhalation pharmaceutical composition
-
The invention relates to a VEGF (vascular endothelial growth factor)-inhibiting dry powder inhalation pharmaceutical composition for treating respiratory diseases, especially for asthma, in particular to a dry powder inhalation pharmaceutical composition containing an active ingredient compound I or physiologically acceptable salts thereof, and one or more pharmaceutically acceptable excipients for dry powder inhalations.
- -
-
Paragraph 0183; 0184; 0185; 0186; 0187; 0218-0222
(2017/07/21)
-
- VEGF (vascular endothelial growth factor)-inhibiting compound
-
The invention relates to a VEGF (vascular endothelial growth factor)-inhibiting compound, belongs to the field of medicine, and in particular relates to a compound of formula I and salts. The invention also relates to a method for synthesizing the compound, uses in drugs and a pharmaceutical preparation, especially for the treatment of tumors and angiogenesis.
- -
-
Paragraph 0167-0172
(2017/07/20)
-
- Dry powder inhalant pharmaceutical composition for vascular endothelial growth factor inhibitor
-
The invention relates to a dry powder inhalant pharmaceutical composition for a vascular endothelial growth factor inhibitor for treating respiratory diseases, particularly asthma and particularly relates to a dry powder inhalant pharmaceutical composition containing an active component compound I, physically acceptable salt thereof and one or several medicine ingredients serving as a powder inhalation.
- -
-
Paragraph 0188; 0189; 0190; 0191; 0192; 0221-0228
(2017/07/21)
-
- Aerosol pharmaceutical composition for inhibiting VEGF
-
The invention belongs to the medical field, particularly relates to an aerosol pharmaceutical composition for inhibiting a compound of formula I (shown in the description) and a salt of a VEGF, pharmaceutical use of the aerosol pharmaceutical composition and a pharmaceutical preparation and particularly aims at treatment of tumors and angiogenesis. The invention further relates to a synthetic method of the compound.
- -
-
Paragraph 0173; 0174; 0175; 0176; 0177; 0178; 0209-0214
(2017/07/19)
-
- Hydrochloride of vascular endothelial growth factor
-
The invention belongs to the field of medicine and particularly relates to hydrochloride of a compound I (shown in the description) of a vascular endothelial growth factor. The invention further relates to a synthetic method of the compound, pharmaceutica
- -
-
Paragraph 0167; 0168; 0169; 0170; 0171; 0172; 0173; 0209-021
(2017/07/19)
-
- A vascular endothelial growth factor inhibitors hydrochloride injection of the pharmaceutical composition (by machine translation)
-
The invention belongs to the field of medicine, in particular to inhibit VEGF of formula I compound hydrochloride injection of the pharmaceutical composition, the pharmaceutical use and pharmaceutical formulations, particularly with respect to the tumor, the treatment of angiogenesis. The invention also relates to the method for synthesizing the compounds. (by machine translation)
- -
-
Paragraph 0179; 0180; 0181; 0182; 0183; 0221; 0222-0224
(2017/07/21)
-
- VEGF (vascular endothelial growth factor)-inhibiting injection pharmaceutical composition
-
The invention belongs to the field of medicine, in particular relates to a VEGF-inhibiting injection pharmaceutical composition containing a compound of formula I and salts, uses in drugs and a pharmaceutical preparation, especially for the treatment of t
- -
-
Paragraph 0176; 0177; 0178; 0179-0182; 0212-0217
(2017/07/22)
-
- Aerosol pharmaceutical composition for hydrochloride of vascular endothelial growth factor inhibitor
-
The invention belongs to the field of medicine, particularly relates to an aerosol pharmaceutical composition for inhibiting hydrochloride of a compound of formula I (shown in the description) of a VEGF, pharmaceutical use of the aerosol pharmaceutical composition and a pharmaceutical preparation and particularly aims at treatment of tumors and angiogenesis. The invention further relates to a synthetic method of the compound.
- -
-
Paragraph 0175; 0176; 0177; 0178; 0179; 0218-0222
(2017/07/19)
-